GlassScriptPhysician profile
Anthony Fritz
NPI 1194750901
$2,605.81
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $675 · 2021: $441 · 2023: $570 · 2024: $39.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $570 · Consulting Fee: $20.00 · Food and Beverage: $19.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $570.00 |
| Consulting Fee | $20.00 |
| Food and Beverage | $19.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sekisui Diagnostics LLC | $570.00 | 2023 | |
| Glaxosmithkline, LLC. | $539.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $538.99 | 2019-2021 | |
| Amgen INC. | $129.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $90.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.36 | 2019-2020 | |
| Pfizer INC. | $75.68 | 2019-2020 | |
| Lilly USA, LLC | $58.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $52.74 | 2019-2020 | |
| Novo Nordisk INC | $50.82 | 2019-2024 | Wegovy |
| Allergan, INC. | $50.53 | 2019-2020 | |
| Astellas Pharma US INC | $37.43 | 2019-2020 | |
| Braintree Laboratories, INC. | $33.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.33 | 2019 | |
| Philips North America LLC | $24.63 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.46 | 2019 | |
| Amarin Pharma, INC. | $19.03 | 2021 | |
| Merck Sharp & Dohme LLC | $18.88 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.01 | 2019 | |
| Circassia INC. | $16.70 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.29 | 2019 | |
| Corcept Therapeutics | $15.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.73 | 2019 | |
| Abbvie INC. | $14.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2019 | |
| Horizon Therapeutics Plc | $14.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.78 | 2019 | |
| Neurocrine Biosciences, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Fritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.